Hanahan, D. & Weinberg, R. A. Hallmarks of most cancers: the subsequent era. Cell 144, 646–674 (2011).
Vasan, N., Baselga, J. & Hyman, D. M. A view on drug resistance in most cancers. Nature 575, 299–309 (2019).
Boumahdi, S. & de Sauvage, F. J. The good escape: tumour cell plasticity in resistance to focused remedy. Nat. Rev. Drug Discov. 19, 39–56 (2019).
Robey, R. W. et al. Revisiting the position of ABC transporters in multidrug-resistant most cancers. Nat. Rev. Most cancers 18, 452–464 (2018).
Takebe, N. et al. Concentrating on Notch, Hedgehog, and Wnt pathways in most cancers stem cells: medical replace. Nat. Rev. Clin. Oncol. 12, 445–464 (2015).
Hangauer, M. J. et al. Drug-tolerant persister most cancers cells are weak to GPX4 inhibition. Nature 551, 247–250 (2017).
Bugter, J. M., Fenderico, N. & Maurice, M. M. Mutations and mechanisms of WNT pathway tumour suppressors in most cancers. Nat. Rev. Most cancers 21, 5–21 (2020).
Rijsewijk, F. et al. The Drosophila homolog of the mouse mammary oncogene int-1 is equivalent to the phase polarity gene wingless. Cell 50, 649–657 (1987).
Nusse, R. & Varmus, H. E. Many tumors induced by the mouse mammary tumor virus include a provirus built-in in the identical area of the host genome. Cell 31, 99–109 (1982).
Nusse, R. & Clevers, H. Wnt/β-catenin signaling, illness, and rising therapeutic modalities. Cell 169, 985–999 (2017).
Carmon, Okay. S., Gong, X., Yi, J., Thomas, A. & Liu, Q. RSPO–LGR4 features by way of IQGAP1 to potentiate Wnt signaling. Proc. Natl Acad. Sci. USA 111, E1221–E1229 (2014).
Zhao, H. et al. Wnt signaling in colorectal most cancers: pathogenic position and therapeutic goal. Mol. Most cancers 21, 144 (2022).
Yeung, J. et al. β-Catenin mediates the institution and drug resistance of MLL leukemic stem cells. Most cancers Cell 18, 606–618 (2010).
Stein, U. et al. Affect of mutant β-catenin on ABCB1 expression and remedy response in colon most cancers cells. Br. J. Most cancers 106, 1395–1405 (2012).
Wielenga, V. J. et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 154, 515–523 (1999).
Du, L. et al. CD44 is of useful significance for colorectal most cancers stem cells. Clin. Most cancers Res. 14, 6751–6760 (2008).
Pich, O. et al. The translational challenges of precision oncology. Most cancers Cell 40, 458–478 (2022).
Ward, R. A. et al. Challenges and alternatives in most cancers drug resistance. Chem. Rev. 121, 3297–3351 (2021).
Dixon, S. J. et al. Ferroptosis: an iron-dependent type of nonapoptotic cell demise. Cell 149, 1060–1072 (2012).
Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014).
Ingold, I. et al. Selenium utilization by GPX4 is required to forestall hydroperoxide-induced ferroptosis. Cell 172, 409–422 (2018).
Yang, W. S. et al. Regulation of ferroptotic most cancers cell demise by GPX4. Cell 156, 317–331 (2014).
Lim, J. Okay. M. et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox steadiness. Proc. Natl Acad. Sci. USA 116, 9433–9442 (2019).
Wu, J. et al. Intercellular interplay dictates most cancers cell ferroptosis by way of NF2–YAP signalling. Nature 572, 402–406 (2019).
Jiang, L. et al. Ferroptosis as a p53-mediated exercise throughout tumour suppression. Nature 520, 57–62 (2015).
Stockwell, B. R. Ferroptosis turns 10: rising mechanisms, physiological features, and therapeutic functions. Cell 185, 2401–2421 (2022).
Lei, G., Zhuang, L. & Gan, B. Concentrating on ferroptosis as a vulnerability in most cancers. Nat. Rev. Most cancers 22, 381–396 (2022).
Friedmann Angeli, J. P., Krysko, D. V. & Conrad, M. Ferroptosis on the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Most cancers 19, 405–414 (2019).
Viswanathan, V. S. et al. Dependency of a therapy-resistant state of most cancers cells on a lipid peroxidase pathway. Nature 547, 453–457 (2017).
Rodriguez, R., Schreiber, S. L. & Conrad, M. Persister most cancers cells: iron habit and vulnerability to ferroptosis. Mol. Cell 82, 728–740 (2022).
Barker, N. et al. Identification of stem cells in small gut and colon by marker gene Lgr5. Nature 449, 1003–1007 (2007).
de Lau, W. et al. Lgr5 homologues affiliate with Wnt receptors and mediate R-spondin signalling. Nature 476, 293–297 (2011).
Yan, Okay. S. et al. Non-equivalence of Wnt and R-spondin ligands throughout Lgr5+ intestinal stem-cell self-renewal. Nature 545, 238–242 (2017).
Sato, T. et al. Lengthy-term growth of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772 (2011).
Sasaki, N. & Clevers, H. Learning mobile heterogeneity and drug sensitivity in colorectal most cancers utilizing organoid know-how. Curr. Opin. Genet. Dev. 52, 117–122 (2018).
Yao, Y. et al. Affected person-derived organoids predict chemoradiation responses of domestically superior rectal most cancers. Cell Stem Cell 26, 17–26 (2020).
Cheng, Q. et al. LGR4 cooperates with PrPc to endow the stemness of colorectal most cancers stem cells contributing to tumorigenesis and liver metastasis. Most cancers Lett. 540, 215725 (2022).
Roerink, S. F. et al. Intra-tumour diversification in colorectal most cancers on the single-cell degree. Nature 556, 457–462 (2018).
Jenkins, R. W. et al. Ex vivo profiling of PD-1 blockade utilizing organotypic tumor spheroids. Most cancers Discov. 8, 196–215 (2018).
Wang, D. & Lippard, S. J. Mobile processing of platinum anticancer medicine. Nat. Rev. Drug Discov. 4, 307–320 (2005).
Hwang, P. M. et al. Ferredoxin reductase impacts p53-dependent, 5-fluorouracil-induced apoptosis in colorectal most cancers cells. Nat. Med. 7, 1111–1117 (2001).
Feng, H. et al. Transferrin receptor is a particular ferroptosis marker. Cell Rep. 30, 3411–3423 (2020).
Anastas, J. N. & Moon, R. T. WNT signalling pathways as therapeutic targets in most cancers. Nat. Rev. Most cancers 13, 11–26 (2013).
Kahn, M. Can we safely goal the WNT pathway? Nat. Rev. Drug Discov. 13, 513–532 (2014).
Harnack, C. et al. R-spondin 3 promotes stem cell restoration and epithelial regeneration within the colon. Nat. Commun. 10, 4368 (2019).
Salik, B. et al. Concentrating on RSPO3-LGR4 signaling for leukemia stem cell eradication in acute myeloid leukemia. Most cancers Cell 38, 263–278 (2020).
Hassannia, B., Vandenabeele, P. & Vanden Berghe, T. Concentrating on ferroptosis to iron out most cancers. Most cancers Cell 35, 830–849 (2019).
Zhang, Y. et al. BAP1 hyperlinks metabolic regulation of ferroptosis to tumour suppression. Nat. Cell Biol. 20, 1181–1192 (2018).
Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to most cancers therapies. Nat. Rev. Clin. Oncol. 15, 81–94 (2017).
Yu, F. et al. Dynamic O-GlcNAcylation coordinates ferritinophagy and mitophagy to activate ferroptosis. Cell Discov. 8, 40 (2022).
Rao, G. H. et al. Institution of a human colorectal most cancers cell line P6C with stem cell properties and resistance to chemotherapeutic medicine. Acta Pharmacol. Sin. 34, 793–804 (2013).
van de Wetering, M. et al. Potential derivation of a residing organoid biobank of colorectal most cancers sufferers. Cell 161, 933–945 (2015).
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R bundle for evaluating organic themes amongst gene clusters. Omics 16, 284–287 (2012).
De Summa, S. et al. GATK onerous filtering: tunable parameters to enhance variant calling for subsequent era sequencing focused gene panel information. BMC Bioinform. 18, 119 (2017).
Kim, J. Y. et al. HDAC8 deacetylates HIF-1α and enhances its protein stability to advertise tumor development and migration in melanoma. Cancers 15, 1123 (2023).
Rescigno, P. et al. Characterizing CDK12-mutated prostate cancers. Clin. Most cancers Res. 27, 566–574 (2021).
de Sousa e Melo, F. et al. A definite position for Lgr5(+) stem cells in major and metastatic colon most cancers. Nature 543, 676–680 (2017).
Du, L. et al. CD44-positive most cancers stem cells expressing mobile prion protein contribute to metastatic capability in colorectal most cancers. Most cancers Res. 73, 2682–2694 (2013).
Yi, Z. et al. LGR4 promotes tumorigenesis by activating TGF-β1/Smad signaling pathway in a number of myeloma. Cell. Signalling 110, 110814 (2023).
Goldman, M. J. et al. Visualizing and decoding most cancers genomics information by way of the Xena platform. Nat. Biotechnol. 38, 675–678 (2020).
